References
- LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
- MatzaLSPhillipsGARevickiDADeveloping a clinician-reported measure of reasons for antipsychotic discontinuation or continuation in the treatment of schizophreniaPresented at the Collegium Internationale Neuro-Psychopharmacologicum Biennial International CongressChicago, ILJuly 9–13, 2006
- MatzaLSPhillipsGARevickiDADeveloping a patient interview to assess reasons for antipsychotic discontinuation or continuation in the treatment of schizophreniaSchizophr Bull2007332595596
- Ascher-SvanumHNyhuisAFariesDReasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectivesCurr Med Res Opin201026102403241020812791
- HoffmannVPCaseMJacobsonJGAssessment of the safety, efficacy and practicality of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain during treatment with olanzapine in outpatients with schizophreniaJ Clin Psychiatry5172011 [Epub ahead of print.]
- FariesDAscher-SvanumHNyhuisAAndersonJPhillipsGThe validation of a measure assessing reasons for antipsychotic discontinuation and continuation from patient’s and clinician’s perspectivesPresented at the Winter Workshop in PsychosesBarcelona, SpainNovember 15–18, 2009
- MatzaLPhillipsGARevickiDDevelopment of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuationPsychiatry Res2011189346346821684017
- OverallJEGorhamDRThe Brief Psychiatric Rating ScalePsychol Rep196210799812
- Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
- PerkinsDOGuHWeidenPJMcEvoyJPHamerRMLiebermanJAPredictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter studyJ Clin Psychiatry200869110611318312044
- PerkinsDOJohnsonJLHamerRMPredictors of antipsychotic medication adherence in patients recovering from a first psychotic episodeSchizophr Res2006831536316529910
- RossiAVitaATiradrittiPRomeoFAssessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidoneInt Clin Psychopharmacol200823421622218545060
- RosenheckRChangSChoeYMedication continuation and compliance: a comparison of patients treated with clozapine and haloperidolJ Clin Psychiatry200061538238610847315
- LofflerWKilianRToumiMAngermeyerMCSchizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatmentPharmacopsychiatry200336310511212806568
- Liu-SeifertHHoustonJPAdamsDHKinonBJAssociation of acute symptoms and compliance attitude in noncompliant patients with schizophreniaJ Clin Psychopharmacol200727439239417632224
- KarowACzekallaJDittmannRWAssociation of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophreniaJ Clin Psychiatry2007681758017284133
- KinonBJChenLAscher-SvanumHEarly response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophreniaNeuropsychopharmacology200935258159019890258
- CampbellECDejesusMHermanBKA pilot study of antipsychotic prescribing decisions for acutely-ill hospitalized patientsProg Neuropsychopharmacol Biol Psychiatry201135124625121108980